Peptide Lab HQ Research Guide
ARA-290
A research-focused compound profile covering ARA-290 identity, Cibinetide research, innate repair receptor signaling, small-fiber neuropathy models, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | ARA-290 |
|---|---|
| Synonyms | Cibinetide, PHBSP, pyroglutamate helix B surface peptide, helix B surface peptide |
| Compound Type | Erythropoietin-derived non-hematopoietic peptide |
| CAS Number | 1208243-50-8 |
| PubChem CID | 91810664 |
| Amino Acid Length | 11 amino acids |
| Amino Acid Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Short Sequence | ZEQLERALNSS |
| Molecular Formula | C₅₁H₈₄N₁₆O₂₁ |
| Molecular Weight | Approximately 1257.3 g/mol |
| Research Category | Innate repair receptor, EPOR/CD131, small-fiber neuropathy, neuroprotection, inflammation, and tissue-protection research |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
ARA-290 is commonly discussed in controlled research models involving innate repair receptor signaling, EPOR/CD131 pathway activity, small-fiber neuropathy, neuroprotection, anti-inflammatory signaling, and tissue-protective response pathways.
Innate Repair Receptor Research
ARA-290 is commonly studied around tissue-protective receptor signaling involving EPOR and CD131 pathway context.
Small-Fiber Neuropathy Models
Cibinetide has been evaluated in sarcoidosis-associated small-fiber neuropathy research involving neuropathic symptoms and nerve-fiber related endpoints.
Neuroprotection Research
ARA-290 appears in neuroprotection research involving nerve injury, retinal models, CNS injury models, and neuronal survival signaling.
Inflammatory Pathway Models
Used in research contexts involving inflammatory signaling, cytokine response, immune-cell function, and tissue-injury resolution.
Tissue-Protection Studies
Commonly discussed in models involving tissue repair, cytoprotection, anti-apoptotic signaling, fibrosis, and injury-response pathways.
Metabolic / Aging Research
ARA-290 has been evaluated in animal research involving inflammation, fibrosis, cardiac aging, insulin-resistance context, and healthspan-related markers.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on model type, route, timing, purity, concentration, formulation, and laboratory conditions.
Research Applications
Key Research Applications
ARA-290 is commonly discussed in controlled research models involving innate repair receptor signaling, EPOR/CD131 pathway activity, small-fiber neuropathy, neuroprotection, anti-inflammatory signaling, and tissue-protective response pathways.
Innate Repair Receptor Research
ARA-290 is commonly studied around tissue-protective receptor signaling involving EPOR and CD131 pathway context.
Small-Fiber Neuropathy Models
Cibinetide has been evaluated in sarcoidosis-associated small-fiber neuropathy research involving neuropathic symptoms and nerve-fiber related endpoints.
Neuroprotection Research
ARA-290 appears in neuroprotection research involving nerve injury, retinal models, CNS injury models, and neuronal survival signaling.
Inflammatory Pathway Models
Used in research contexts involving inflammatory signaling, cytokine response, immune-cell function, and tissue-injury resolution.
Tissue-Protection Studies
Commonly discussed in models involving tissue repair, cytoprotection, anti-apoptotic signaling, fibrosis, and injury-response pathways.
Metabolic / Aging Research
ARA-290 has been evaluated in animal research involving inflammation, fibrosis, cardiac aging, insulin-resistance context, and healthspan-related markers.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on model type, route, timing, purity, concentration, formulation, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 10 mg ARA-290 |
|---|---|
| Primary Solution Volume | 2 mL bacteriostatic water |
| Primary Concentration | 5 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 5 mg/mL, 1 unit equals 0.05 mg / 50 mcg ARA-290. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | ARA-290, also referenced as Cibinetide | ARA-290 is commonly discussed as an erythropoietin-derived peptide analog in tissue-protective, inflammatory-marker, and receptor-associated research contexts. |
| Innate Repair Receptor Research | Model-dependent concentration and endpoint tracking | Research discussions commonly include tissue-protective signaling, cytokine markers, neuropathy models, endothelial response, and inflammatory-marker tracking. |
| Neural / Tissue-Protection Research | Experimental and model-dependent context | ARA-290-related research commonly appears in neuroprotection, small-fiber, metabolic-stress, pain-model, and tissue-response contexts. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references are not clinical dosing standards and should not be treated as research-chemical use instructions. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, clinical-use references, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 10 mg | 2 mL | 5 mg/mL |
| 16 mg | 3 mL | 5.33 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 5 mg/mL | U-100 Unit Reference | Approx. References per 10 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.10 mL | 10 units | 20 |
| 1 mg / 1000 mcg | 0.20 mL | 20 units | 10 |
| 2 mg / 2000 mcg | 0.40 mL | 40 units | 5 |
| 4 mg / 4000 mcg | 0.80 mL | 80 units | 2.5 |
| 5 mg / 5000 mcg | 1.00 mL | 100 units | 2 |
| 8 mg / 8000 mcg | 1.60 mL | 160 units | 1.2 |
| 10 mg / 10000 mcg | 2.00 mL | 200 units | 1 |
| 16 mg / 16000 mcg | 3.20 mL | 320 units | 0.6 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg / 500 mcg reference amount | 10 units / 0.10 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg / 1000 mcg reference amount | 20 units / 0.20 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 2 mg / 2000 mcg reference amount | 40 units / 0.40 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 4 mg / 4000 mcg reference amount | 80 units / 0.80 mL |
| Upper Conversion Example | Public protocol-style reference, not a clinical dosing standard | 8 mg / 8000 mcg reference amount | 160 units / 1.60 mL |
| High Conversion Example | Public protocol-style reference, not a clinical dosing standard | 16 mg / 16000 mcg reference amount | 320 units / 3.20 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Marker Observation Window | 24–72 hours | May be used for cytokine-response, receptor-associated signaling, endothelial response, cellular-stress markers, or tissue-response documentation depending on the model. |
| Acute Observation Window | Single session to several days | Used for short-term response tracking, timing comparison, early marker observation, or preparation comparison depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for early controlled observation involving inflammatory-marker, tissue-protective, small-fiber, endothelial, or metabolic-stress endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for tissue-protective marker trends, inflammatory-marker context, neural-response, or follow-up marker tracking. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. ARA-290, also referenced as Cibinetide, is commonly discussed in tissue-protective signaling, innate repair receptor, inflammatory-marker, endothelial-response, neuropathy-model, and cellular-stress research contexts. The selector above updates calculations for 10 mg reconstituted with 2.0 mL bacteriostatic water and 16 mg reconstituted with 3.0 mL bacteriostatic water. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
ARA-290 is commonly discussed in research involving innate repair receptor signaling, EPOR/CD131 pathway activity, small-fiber neuropathy, neuroprotection, anti-inflammatory signaling, tissue repair, fibrosis, and injury-response models.
Study Limitations
ARA-290 research includes clinical studies, animal models, and mechanistic investigations. Findings should be interpreted according to route, formulation, study design, population, and endpoint selection.
Safety Considerations
Laboratory handling should include appropriate PPE, clean technique, proper labeling, batch documentation, and qualified research procedures. Clinical-study references should not be treated as universal research-chemical protocols.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.